Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation

Similar Items

• Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
  od: Lin L, i dr.
  Izdano: (2020-09-01)
• Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
  od: Lin, Ling, i dr.
  Izdano: (2020)
• Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
  od: Hochmair, Maximilian J., i dr.
  Izdano: (2018)
• Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study
  od: Thongprasert, Sumitra, i dr.
  Izdano: (2019)
• Anti-tumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 Insertions
  od: Floc’h, Nicolas, i dr.
  Izdano: (2018)